<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629768</url>
  </required_header>
  <id_info>
    <org_study_id>S63851</org_study_id>
    <nct_id>NCT04629768</nct_id>
  </id_info>
  <brief_title>Purastat Prevention Delayed Bleeding Duodenum</brief_title>
  <official_title>A Study to Evaluate the Effectiveness of Purastat® in the Prevention of Delayed Bleeding After EMR of Non-ampullary Duodenal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Raf Bisschops</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>3-D Matrix Europe SAS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PuraStat is a viscous solution of synthetic peptides that provides a physical barrier to&#xD;
      facilitate hemostasis. It is indicated for haemostasis in a variety of surgical indications.&#xD;
      In this study the efficacy of PuraStat in reducing delayed bleeding following duodenal&#xD;
      endoscopic mucosal resection (EMR) will be assessed. PuraStat will be applied to the EMR&#xD;
      defect after the resection. The presence of active bleeding or high risk stigma of bleeding&#xD;
      will be observed on an esophagogastroduodenoscopy (EGD) performed 1 day after the duodenal&#xD;
      EMR. Furthermore the presence of clinical signs of delayed bleeding, other adverse events and&#xD;
      the feasibility of PuraStat application will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of active bleeding or high risk stigma of bleeding</measure>
    <time_frame>1 day after EMR</time_frame>
    <description>On an EGD, performed the day after the duodenal EMR with PuraStat application, the presence of active bleeding or the presence of visible vessels after removal of a blood clot will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of clinical signs of delayed bleeding</measure>
    <time_frame>'During hospital stay, assessed up to 10 days' and '30 days after EMR'</time_frame>
    <description>The presence of hematemesis, melena, hemoglobin/hematocrit drop, hypotension or shock will be observed in the patients that had duodenal EMR with PuraStat application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence of other adverse events</measure>
    <time_frame>'During hospital stay, assessed up to 10 days' and '30 days after EMR'</time_frame>
    <description>The presence of adverse events like perforation, severe pain, fever… will be observed in the patients that had duodenal EMR with Purastat application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The feasibility of PuraStat application: Amount</measure>
    <time_frame>During EMR procedure</time_frame>
    <description>The amount of PuraStat will be investigated: Volume in mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The feasibility of PuraStat application: Ease</measure>
    <time_frame>During EMR procedure</time_frame>
    <description>The ease of application will be investigated: Questionnaire will be answered by the endoscopist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The feasibility of Purastat application: Coverage</measure>
    <time_frame>During EGD procedure</time_frame>
    <description>Is PuraStat covering the resection defect the day after the EMR? This will be investigated by questionnaire that will be answered by the endoscopist who performs the EGD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Lesion; Duodenum</condition>
  <arm_group>
    <arm_group_label>Duodenal EMR + PuraStat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PuraStat will be applied to the defect after duodenal EMR of the lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PuraStat</intervention_name>
    <description>Purastat is applied to the EMR defect</description>
    <arm_group_label>Duodenal EMR + PuraStat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Duodenal non-ampullary mucosal lesion ≥ 10 mm&#xD;
&#xD;
          -  ≥ 18y of age&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ampulloma&#xD;
&#xD;
          -  Submucosal lesion&#xD;
&#xD;
          -  Lesion &lt; 10 mm&#xD;
&#xD;
          -  &gt;1 lesion resected&#xD;
&#xD;
          -  Active use of anticoagulant or antithrombotic medication other than aspirin&#xD;
&#xD;
          -  Known clotting disorder&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  &lt; 18y of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Demedts</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raf Bisschops</last_name>
    <phone>+3216342161</phone>
    <email>raf.bisschops@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid Demedts</last_name>
    <phone>+3216345518</phone>
    <email>ingrid.demedts@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raf Bisschops, MD PhD</last_name>
      <phone>+3216342161</phone>
      <email>raf.bisschops@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Demedts, MD PhD</last_name>
      <phone>+3216345518</phone>
      <email>ingrid.demedts@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Raf Bisschops, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Demedts, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Raf Bisschops</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Purastat</keyword>
  <keyword>EMR duodenum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

